[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350317-105":59,"doc-detail-350317-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-chk1-inhibitor-prexasertib-is-effective-against-in-vitro-models-of-aggressive-thyroid-carcinomas-with-defective-p53-function","The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function","","Prexasertib, a selective CHK1 kinase inhibitor, was evaluated in vitro as a potential therapy for aggressive thyroid carcinomas with defective p53 function. Tyrosine kinase inhibitors are often ineffective due to primary or acquired resistance, motivating exploration of the DNA damage response pathway. Using p53-defective and p53-proficient thyroid cancer cell lines, investigators assessed genomic instability, DNA repair signaling, proliferation, and cell death. Results show p53-defective cells rely on ATR/CHK1-mediated repair, making them more sensitive to Prexasertib, with Doxorubicin enhancing effects at low doses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-chk1-inhibitor-prexasertib-is-effective-against-in-vitro-models-of-aggressive-thyroid-carcinomas-with-defective-p53-function/350317/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-chk1-inhibitor-prexasertib-is-effective-against-in-vitro-models-of-aggressive-thyroid-carcinomas-with-defective-p53-function/350317.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why target CHK1 in aggressive thyroid cancers with defective p53?","Question",{"text":112,"@type":113},"When p53 function is lost, tumor cells depend more on DNA damage response kinases to repair potentially lethal lesions, enabling survival. CHK1 (ATR/CHK1 axis) becomes a key vulnerability in this context.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the DNA damage response evaluated in the study?",{"text":117,"@type":113},"The DNA damage response was characterized in p53-defective and p53-proficient thyroid cancer cell lines using western blot and immunofluorescence, and cell viability was assessed with an MTT-based assay.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings for Prexasertib alone and with Doxorubicin?",{"text":121,"@type":113},"Prexasertib significantly reduced proliferation and induced cell death more effectively in p53-defective cells, linked to replicative failure. Doxorubicin potentiated Prexasertib effects in p53-defective cells, even at the lowest doses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350317,1790628526,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Original Research PUBLISHED 08 May 2026  \nDOI 10.3389/fendo.2026.1743111  \nOPEN ACCESS  \nEDITED BY  \nVladimir Neychev,  \nUniversity of Central Florida, United States  \nREVIEWED BY  \nFengchao Lang,  \nNational Institutes of Health (NIH), United States  \nChia-Yih Wang,  \nNational Cheng Kung University, Taiwan  \n*CORRESPONDENCE  \nValentina Cirello  \n [v.cirello@auxologico.it](v.cirello@auxologico.it)  \nRECEIVED 10 November 2025  \nREVISED 17 April 2026  \nACCEPTED 21 April 2026  \nPUBLISHED 08 May 2026  \nCITATION  \nManzo A, Grassi ES, Borghi MO, Colombo C, Persani L and Cirello V (2026) The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function.  \nFront. Endocrinol. 17:1743111 .  \ndoi: 10.3389/fendo.2026.1743111  \nCOPYRIGHT  \n© 2026 Manzo, Grassi, Borghi, Colombo, Persani and Cirello. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function  \nAlessandro Manzo 1, Elisa Stellaria Grassi 2, Maria Orietta Borghi 3,4, Carla Colombo 2,5, Luca Persani 1,2 and Valentina Cirello 2,5*  \n1 Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy,  \n2 Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy, 3 Immunorheumatology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy,  \n4 Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan, Italy, 5 Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy  \nIntroduction: Tyrosine kinase inhibitors represent the most effective and longlasting treatment currently available for aggressive thyroid cancers, but in some patients the response is poor or absent. Recently, we demonstrated that the response to Lenvatinib is associated with alterations in TP53 gene or protein. Aiming to ﬁnd a novel therapeutic strategy for aggressive thyroid cancers, we investigated in vitro the DNA damage response pathway, where p53 plays a crucial role, and tested its inhibition through synthetic lethality or stress sensitization strategies.  \nMethods: The DNA damage response has been characterized in a panel of p53-defective or proﬁcient thyroid cancer cell lines both at basal level and in response to Doxorubicin, a DNA damaging agent, by western blot, immunoﬂuorescence and MTT-based cell viability assay. We then evaluated the effect of a selective CHK1 kinase inhibitor, Prexasertib, either alone or in combination with Doxorubicin. Cell cycle variations and cell death were evaluated by ﬂow-cytometry.  \nResults: The p53-defective thyroid cancer cells showed a higher degree of genomic instability and, in response to Doxorubicin, activated not only ATM/ CHK2 but also ATR/CHK1 to bypass p53 and induce DNA repair. We found that Prexasertib was more effective in p53-defective cells, since it signiﬁcantly reduced tumor cell proliferation due to replicative failure and cell death. Moreover, Doxorubicin potentiated the Prexasertib effects in p53-defective thyroid cancer cells, yet at the lowest doses.  \nConclusions: This study unravels the potential of Prexasertib as a novel treatment option for aggressive thyroid cancers p53-defective and poorly responsive to tyrosine kinase inhibitors.  \nKEYWORDS  \nCHK1, DNA damage response, Prexasertib, thyroid cancer, TP53, tyrosine kinase inhibitors  \nFrontiers in Endocrinology 01 [frontiersin.org](frontiersin.org)  \n1 Intr","cbCaivFAh5qU8DFD","https://ap.wps.com/l/cbCaivFAh5qU8DFD","pdf",8041581,13,"English","# Introduction\n## Thyroid cancer treatment limitations\n## TP53 alterations and DDR pathway rationale\n# Methods\n## Cell line models and DNA damage induction\n## CHK1 inhibition and combination design\n# Results\n## Genomic instability and DDR activation\n## Prexasertib efficacy and combination effects\n# Conclusions","[{\"question\":\"Why target CHK1 in aggressive thyroid cancers with defective p53?\",\"answer\":\"When p53 function is lost, tumor cells depend more on DNA damage response kinases to repair potentially lethal lesions, enabling survival. CHK1 (ATR/CHK1 axis) becomes a key vulnerability in this context.\"},{\"question\":\"How was the DNA damage response evaluated in the study?\",\"answer\":\"The DNA damage response was characterized in p53-defective and p53-proficient thyroid cancer cell lines using western blot and immunofluorescence, and cell viability was assessed with an MTT-based assay.\"},{\"question\":\"What were the main findings for Prexasertib alone and with Doxorubicin?\",\"answer\":\"Prexasertib significantly reduced proliferation and induced cell death more effectively in p53-defective cells, linked to replicative failure. Doxorubicin potentiated Prexasertib effects in p53-defective cells, even at the lowest doses.\"}]","The CHK1 inhibitor Prexasertib is effective against in vitro models of aggressive thyroid carcinomas with defective p53 function | PDF",1790088416,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9279192ccbb031e58be4c59ff5c4be73.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66511f932c726a2cde403869f0d33b6f.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/254aa4fcbb79dab4a953948a1813ee5c.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5a1eaf9177af4f4766853ad72be844a.webp",980,1385]